Physician profile
William W Maclaughlin
NPI 1164487419
$2,344.71
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $222 · 2021: $808 · 2022: $95.00 · 2023: $38.57 · 2024: $31.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $329.88 | 2019-2022 | |
| Taiho Oncology, INC. | $185.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $167.27 | 2019-2021 | |
| Glaxosmithkline, LLC. | $160.00 | 2021 | |
| Genentech USA, INC. | $157.81 | 2019-2024 | Phesgo |
| Novartis Pharmaceuticals Corporation | $142.52 | 2019-2023 | |
| Janssen Biotech, INC. | $128.30 | 2019-2022 | |
| Seagen INC. | $113.37 | 2019-2022 | |
| Amgen INC. | $97.00 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $95.99 | 2019-2021 | |
| Pfizer INC. | $84.63 | 2019-2021 | |
| Incyte Corporation | $65.92 | 2019-2021 | |
| Daiichi Sankyo INC. | $62.23 | 2019-2021 | |
| Celgene Corporation | $56.54 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $53.61 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $44.80 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $32.09 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $30.26 | 2020-2021 | |
| Coherus Oncology, INC. | $24.88 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.43 | 2020 | |
| Lilly USA, LLC | $23.72 | 2019 | |
| Spectrum Pharmaceuticals INC. | $23.62 | 2019 | |
| Partner Therapeutics, INC. | $23.16 | 2020 | |
| Stemline Therapeutics INC. | $21.82 | 2023 | Orserdu |
| Merck Sharp & Dohme LLC | $18.17 | 2019 | |
| Abbvie INC. | $17.86 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.53 | 2019 | |
| Acceleron Pharma, INC. | $16.57 | 2021 | |
| Verastem, INC. | $16.44 | 2019 | |
| Global Blood Therapeutics, INC. | $16.07 | 2020 | |
| Csl Behring | $14.34 | 2019 | |
| Emd Serono, INC. | $14.04 | 2019 | |
| Mylan Institutional INC. | $13.93 | 2020 | |
| Astellas Pharma US INC | $13.91 | 2019 | |
| Rigel Pharmaceuticals, INC. | $13.59 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.08 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Maclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.